Dynavax (DVAX) Will Present SD-101 Phase 1/2 Data at ASH 2016

November 30, 2016 7:07 AM EST

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Dynavax Technologies Corporation (NASDAQ: DVAX) announced that it will present clinical data from a Phase 1/2 clinical trial evaluating its immuno-oncology product, SD-101, in patients with low-grade, B cell lymphoma. The poster presentation will be made at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition.

  • Abstract Name: SD-101, a Novel Class C CpG-Oligodeoxynucleotide Toll-like Receptor 9 Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial
  • Abstract Number: 2974
  • Date and Time: Sunday, December 4, 2016 from 6:00 p.m. EST to 8:00 p.m. EST
  • Session Name: 623. Mantle Cell, Follicular and Other Indolent B-Cell Lymphoma - Clinical Studies: Poster II
  • Location: San Diego Convention Center, Hall GH
  • Note: Abstract will also be published online on December 1, 2016, in the supplemental volume of the journal Blood

About SD-101

SD-101 is Dynavax's proprietary, second-generation, Toll-like Receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. SD-101 activates multiple anti-tumor activities of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its safety and activity.

For information about SD-101 trials that are currently recruiting patients, please visit www.clinicaltrials.gov.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Add Your Comment